Clinical trials: Irritable Bowel Syndrome - Diarrhoea
Irritable Bowel Syndrome
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of…
- Trial name
- NCT03339128
- Testing
- Eluxadoline
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 272 people
- Sponsor
- AbbVie
IBS, Diarrhea Predominant
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant…
- Trial name
- NCT07610434
- Testing
- Chang Ji'an capsule, Chang Ji'an capsule mimic
- Where
- 29 sites in China
- Volunteers
- 636 people
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
Irritable Bowel Syndrome
Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment
This study is a withdrawal randomized clinical trail to evaluate the clinical efficacy and safety of 1.1 chemical drugs N-acetyl glucosamine on Chinese IBS-D patients coming from four centers in chongqing.
- Trial name
- NCT01893606
- Testing
- N-acetyl-D-glucosamine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome
irritable bowel syndrome (IBS) is a well-known risk factor for diseases of the anal region (hemorrhoids, anal fissures, etc.) and large intestine (colon cancer, diverticular disease).
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Mixed
- Trial name
- NCT05646186
- Testing
- Personalized dietary intervention based on microbiome analysis, Low-FODMAP diet
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Medipol University Hospital
Irritable Bowel Syndrome, Functional Diarrhea
Health Education Delivery Methods for a Low Fermentable Carbohydrate Diet in Patients With Functional Bowel Disorders
There is evidence for the use of a diet low in short chain fermentable carbohydrates (low FODMAP diet) in the management of functional gut symptoms, such as abdominal pain and bloating.
- Conditions
- Irritable Bowel Syndrome, Functional Diarrhea, Functional Bowel Disorder
- Trial name
- NCT03694223
- Testing
- Health education delivery methods
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- King's College London
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days.
- Trial name
- NCT00269412
- Testing
- Rifaximin
- Where
- 67 sites in United States
- Volunteers
- 525 people
- Sponsor
- Bausch Health Americas, Inc.
IBS (Irritable Bowel Syndrome), Diarrhea
Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with…
- Trial name
- CURE-IBS-D (NCT07238790)
- Testing
- MITI-001 administration
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Irritable Bowel Syndrome
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
- Trial name
- NCT00399438
- Testing
- BMS-562086
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Irritable Bowel Syndrome With Diarrhea
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-3 (NCT02107196)
- Testing
- Ibodutant 10 mg
- Where
- 127 sites in United States, Bulgaria and 9 more
- Volunteers
- 535 people
- Sponsor
- Menarini Group
Diarrhea-predominant Irritable Bowel Syndrome, Functional Diarrhea
Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial
This trial is to assess the effectiveness of three types of acupuncture for patients with functional diarrhea comparing to a positive drug control.
- Trial name
- NCT01350570
- Testing
- acupuncture, acupuncture group2, acupuncture group3
- Where
- China
- Volunteers
- 449 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial
Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Chronic Diarrhea
- Trial name
- rTMS (NCT07581756)
- Testing
- rTMS group
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
This is a A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea type (IBS-D).The…
- Trial name
- NCT05923892
- Testing
- OPS-2071
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Otsuka Beijing Research Institute
Irritable Bowel Syndrome
Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial
Evidence exists to support low-grade inflammation as the inciting factor leading to visceral hypersensitivity and alteration in motility in irritable bowel syndrome.In the medical literature,there is ample in vitro and in vivo…
- Trial name
- CuTIBS (NCT00779493)
- Testing
- curcumin
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Irritable Bowel Syndrome With Diarrhoea
Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)
Irritable bowel syndrome is a common condition affecting 1 in 10 of the population. About a third of these suffer from diarrhoea, which severely impairs their quality of life.
- Trial name
- NCT00745004
- Testing
- Ondansetron
- Where
- 2 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- University of Nottingham
Irritable Bowel Syndrome
Mediterranean Diet and the Gut Microbiome
This study will evaluate the impact of a Mediterranean-style diet on microbiome diversity compared to a typical American diet. The study will observe the microbiome composition comparisons in healthy volunteers as well as in…
- Trial name
- NCT03269032
- Testing
- American Diet, Mediterranean-style Diet
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Irritable Bowel Syndrome With Diarrhea
Effects of the Multispecies Probiotic Ecologic Barrier in IBS Patients With Upper GI Symptoms and Anxiety, Depression, or Stress
The aim of this clinical trial is to find out whether Ecologic Barrier is effective in supporting the treatment of irritable bowel syndrome (IBS) in adults.
- Trial name
- NCT07656623
- Testing
- Ecologic Barrier
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Institute of Gastroenterology and Hepatology, Vietnam
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Efficacy of Rifaximin With NAC in IBS-D
The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D).
- Trial name
- NCT06727422
- Testing
- rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Mark Pimentel, MD